US 10,913,709 B2Granted

STAT3 inhibitor formulation

AssigneesThe United States of America, as represented by the Secretary, Department of Health and Human Services, GLG Pharma, LLC, MRIGlobal

InventorsRobert H. Shoemaker, Michael W. Lovell, Jonathan M. White, Shanker Gupta

Life of this patent

Estimating the term…

Abstract

Disclosed is a salt prepared from the STAT3 inhibitor known as 2-hydroxy-4-[[2-[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino] benzoic acid and 2-amino-2-(hydroxymethyl)-1,3-propanediol. The salt is soluble in water and stable for extended periods of time. Further provided are pharmaceutical compositions comprising the salt and methods of administering the salt to prevent and treat cancer, such as breast cancer.

Claims16

Dependent claims

A compound of the formula

Dependencies are inferred from the claim text.

Facts

Application: 16/603,110Filed 5 Apr 2018 · us provisional application
Priority: 5 Apr 2017
Published: US 2020/0109109 A19 Apr 2020
Granted: 9 Feb 2021
Term ends: Not estimatedThe source records don’t support an estimate.

Classification11 codes

A61K 31/197
Having an amino group: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA],…
C07C 309/73
Having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton: to carbon atoms of…
A61K 9/0053
Galenical forms characterised by the site of application: mouth and digestive tract, i.e. intraoral and peroral administration
A61K 9/08
Medicinal preparations characterised by special physical form: solutions

Family

Application62/481,960Us provisional application · filed 5 Apr 2017
US 2020/0109109 A1Pre-grant publication · published 9 Apr 2020
US 10,913,709 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results